This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-25. (canceled)

26. (currently amended) A method for delivering a pharmaceutical polypeptide agent through a body surface, comprising:

(a) providing a synthetic analog of a human growth hormone releasing hormone~~, wherein the human growth hormone releasing hormone includes at least one glutamine residue and the synthetic analog of the human growth hormone releasing hormone has at least one glutamine residue replaced with histidine~~ having at least one glutamine residue at position 16, 30, 31, or 36 replaced with a histidine residue; and

(b) delivering the analog through the body surface by electrotransport.

27-28. (canceled)

29. (new) The method of claim 26 wherein the glutamine residues at positions 31 and 36 of the analog are replaced with histidine residues.

30. (new) The method of claim 26 wherein the hydrophobicity and electrophoretic mobility at the pH of electrotransport of the analog are increased relative to that of the parent polyptptide.

31. (new) The method of claim 26 wherein the analog exhibits at least about the same type and amount of biological activity as the parent polypeptide.

32. (new) The method of claim 26 wherein the overall charge of the analog is positive at a pH in the range of about 5 to 6 but substantially isoelectric at pH 7.4.

33. (new) The method of claim 32 wherein the analog has a greater positive charge at a pH in the range of about 5 to 6 than the parent polypeptide.

34. (new) The method of claim 26 wherein the analog is provided in the form of an anionic donor reservoir formulation for delivering the analog through the body surface by electrotranpsort, the formulation having a pH in the range of about 3.5 to about 7.4.

35. (new) The method of claim 34 wherein the formulation used for delivering the analog by electrotransport has a pH in the range of about 5 to about 7.4.

36. (new) A method for delivering a pharmaceutical polypeptide agent through a body surface, comprising:

(a) providing a synthetic analog of a human growth hormone releasing hormone having at least two glutamine residues at positions 16, 24, 30, 31, or 36 replaced with histidine residues; and

(b) delivering the analog through the body surface by electrotransport.

37. (new) The method of claim 36 wherein the glutamine residues at positions 16, 24, 30, and 31 of the analog are replaced with histidine residues.

38. (new) The method of claim 36 wherein the hydrophobicity and electrophoretic mobility at the pH of electrotransport of the analog are increased relative to that of the parent polyptptide.

39. (new) The method of claim 36 wherein the analog exhibits at least about the same type and amount of biological activity as the parent polypeptide.

40. (new) The method of claim 36 wherein the overall charge of the analog is positive at a pH in the range of about 5 to 6 but substantially isoelectric at pH 7.4.

41. (new) The method of claim 40 wherein the analog has a greater positive charge at a pH in the range of about 5 to 6 than the parent polypeptide.

42. (new) The method of claim 36 wherein the analog is provided in the form of an anionic donor reservoir formulation for delivering the analog through the body surface by electrotranpsort, the formulation having a pH in the range of about 3.5 to about 7.4.

43. (new) The method of claim 42 wherein the formulation used for delivering the analog by electrotransport has a pH in the range of about 5 to about 7.4.